Baird raised the firm’s price target on Neurocrine to $148 from $140 and keeps an Outperform rating on the shares. The firm said the second quarter print was encouraging, with Ingrezza sales exceeding estimates and an increase in the FY2023 guidance range.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine raises 2023 net product sales view to $1.77B-$1.82B
- Neurocrine reports Q2 non-GAAP EPS $1.25, consensus 78c
- Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
- NBIX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tesla downgraded, Netflix upgraded: Wall Street’s top analyst calls